文献速递角膜与眼表疾病

联合角膜缘上皮与基质细胞移植治疗无虹膜相关角膜病变:非随机临床试验

Combined Limbal Epithelial and Stromal Cell Transplant for Aniridia-Related Keratopathy: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2026-01-01

这项单臂开放标签非随机临床试验在9例晚期无虹膜相关角膜病变成人中评估了RAF T-OS(含异体角膜缘上皮干细胞与基质角膜细胞的胶原支架)移植的安全性与可行性。结果显示治疗眼OSS在3个月和12个月较基线下降,未治疗对侧眼无明显变化,BCVA有改善趋势但置信区间包含0,无重大安全性事件。

要点

  • RAF T-OS移植在晚期ARK中可行,3个月OSS较基线下降3.6分,12个月下降2.8分。
  • 未治疗对侧眼OSS无显著变化,支持治疗眼的短期改善趋势。
  • BCVA 12个月平均改善0.47 logMAR,但95%CI跨0,证据不确定。

核心结论

  • RAF T-OS移植在晚期ARK成人中可行,与早期眼表改善相关并部分维持至12个月,无重大安全性担忧。

研究设计与样本

  • 单臂、开放标签非随机临床试验,在英国伦敦三级转诊中心开展,招募期2022年2月至2024年4月,随访12个月。
  • 纳入9例先天性无虹膜合并晚期ARK成人,治疗眼接受RAF T-OS移植,未治疗对侧眼作为自然病史对照。

主要发现

  • 治疗眼平均OSS从基线9.4降至3个月5.9(平均差-3.6,95%CI -5.6至-1.6),12个月为6.7(平均差-2.8,95%CI -4.5至-1.0)。
  • 未治疗对侧眼平均OSS基线8.4,3个月8.4(平均差0,95%CI -2.5至2.5),12个月8.0(平均差-0.4,95%CI -2.4至1.5)。
  • 治疗眼平均BCVA从基线2.23 logMAR(Snellen等效<20/1600)改善至12个月1.77 logMAR(20/1280),平均差-0.47(95%CI -0.97至0.04)。
  • 对侧眼平均BCVA基线1.47 logMAR(20/640),12个月1.44 logMAR(20/640),平均差-0.04(95%CI -0.44至0.37)。
  • 1例早期严重不良事件促使修改生产方案,此后无其他重大RAF T-OS相关安全性事件;2例出现持续性上皮缺损。

临床怎么用

  • 对于晚期无虹膜相关角膜病变成人,RAF T-OS移植可作为探索性治疗选择,需告知证据来自小样本非随机试验。
  • 术后需监测眼表评分与视力变化,并警惕持续性上皮缺损等并发症。

局限性

  • 单臂非随机设计、样本量仅9例,对侧眼自然病史对照非随机化,证据级别有限。
  • 随访仅12个月,BCVA改善的置信区间包含0,长期安全性与疗效尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Advanced aniridia-related keratopathy (ARK) is a progressive ocular surface disorder associated with limbal stem cell deficiency and limited effective treatment options. OBJECTIVE: To evaluate the safety, feasibility, and clinical outcomes of Real Architecture for 3D Tissues-Ocular Surface (RAFT-OS), a tissue-engineered collagen scaffold incorporating allogeneic limbal epithelial stem cells and stromal keratocytes, in adults with advanced ARK. DESIGN, SETTING, AND PARTICIPANTS: This single-arm, open-label nonrandomized clinical trial was conducted at a tertiary referral center in London, United Kingdom. Adults with congenital aniridia and advanced ARK underwent RAFT-OS transplant. Untreated fellow eyes served as natural history comparators. Recruitment occurred between February 2022 and April 2024, with final study completion in April 2025. Follow-up was 12 months. Data analysis was performed from May 2025 through February 2026. INTERVENTION: Surgical transplant of a good manufacturing practice-manufactured RAFT-OS construct. MAIN OUTCOMES AND MEASURES: The primary end points were safety and ocular surface normalization at 3 and 12 months, assessed using the Ocular Surface Score (OSS). Secondary outcomes included best-corrected visual acuity (BCVA, via Early Treatment Diabetic Retinopathy Study [ETDRS] acuity charts) and patient-reported outcomes (Visual Function Questionnaire [VFQ-25], 36-Item Short Form Survey [RAND-36]). RESULTS: Nine participants were included (3 female [33%]; mean [SD] age, 50.6 [11.6] years). One early serious adverse event prompted amendment of the manufacturing protocol; no further major RAFT-OS-related safety events occurred. Two participants developed persistent epithelial defects. In treated eyes, mean (SD) OSS was 9.4 (1.9) at baseline, 5.9 (2.4) at 3 months (mean difference from baseline, -3.6; 95% CI, -5.6 to -1.6), and 6.7 (2.4) at 12 months (mean difference, -2.8; 95% CI, -4.5 to -1.0). In untreated fellow eyes, mean (SD) OSS was 8.4 (2.7) at baseline, 8.4 (2.4) at 3 months (mean difference, 0; 95% CI, -2.5 to 2.5), and 8.0 (2.5) at 12 months (mean difference, -0.4; 95% CI, -2.4 to 1.5). Mean (SD) treated eye BCVA was 2.23 (0.16) logMAR (Snellen equivalent, <20/1600) at baseline and 1.77 (0.67) logMAR (20/1280) at 12 months (mean difference, -0.47; 95% CI, -0.97 to 0.04). Mean (SD) fellow eye BCVA was 1.47 (0.71) logMAR (Snellen equivalent, 20/640) at baseline and 1.44 (0.75) logMAR (20/640) at 12 months (mean difference, -0.04; 95% CI, -0.44 to 0.37). CONCLUSIONS AND RELEVANCE: In this 9-participant nonrandomized clinical trial, RAFT-OS transplant was feasible and associated with early ocular surface improvement, partly sustained through 12 months, without substantial safety concerns. Additional controlled studies with longer follow-up are needed to define safety and clinical effects. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05044598.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kaye AE, Morgan L, Shah R, et al. Combined Limbal Epithelial and Stromal Cell Transplant for Aniridia-Related Keratopathy: A Nonrandomized Clinical Trial. JAMA Ophthalmol. 2026. PMID: 42490097. doi:10.1001/jamaophthalmol.2026.2701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。